Suppr超能文献

重新审视2型神经纤维瘤病的诊断标准以排除与LZTR1相关的神经鞘瘤病。

Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.

作者信息

Smith Miriam J, Bowers Naomi L, Bulman Michael, Gokhale Carolyn, Wallace Andrew J, King Andrew T, Lloyd Simon K L, Rutherford Scott A, Hammerbeck-Ward Charlotte L, Freeman Simon R, Evans D Gareth

机构信息

From the Centre for Genomic Medicine, Division of Evolution and Genomic Science, School of Biological Sciences, St Mary's Hospital (M.J.S., N.L.B., M.B., C.G., A.J.W., D.G.E.), Department of Otolaryngology, Manchester Royal Infirmary (S.K.L.L., S.R.F.), and the Department of Neurosurgery, Salford Royal Foundation Trust (A.T.K., S.A.R., C.L.H.-W.), Manchester Academic Health Sciences Centre, University of Manchester, UK.

出版信息

Neurology. 2017 Jan 3;88(1):87-92. doi: 10.1212/WNL.0000000000003418. Epub 2016 Nov 16.

Abstract

OBJECTIVE

To determine the specificity of the current clinical diagnostic criteria for neurofibromatosis type 2 (NF2) relative to the requirement for unilateral vestibular schwannoma (VS) and at least 2 other NF2-related tumors.

METHODS

We interrogated our Manchester NF2 database, which contained 205 individuals meeting NF2 criteria who initially presented with a unilateral VS. Of these, 83 (40.7%) went on to develop a contralateral VS. We concentrated our genetic analysis on a group of 70 who initially fulfilled NF2 criteria with a unilateral vestibular schwannoma and at least 2 additional nonintradermal schwannomas.

RESULTS

Overall, 5/70 (7%) individuals with unilateral VS and at least 2 other schwannomas had a pathogenic or likely pathogenic LZTR1 mutation. Twenty of the 70 subsequently developed bilateral disease. Of the remaining 50, 5 (10%) had a germline LZTR1 mutation, equivalent to the number (n = 5) with a germline NF2 mutation.

CONCLUSIONS

The most common etiology for unilateral VS and 2 additional NF2-associated tumors in this cohort was mosaic NF2. Germline LZTR1 and germline NF2 mutations were equally common in our cohort. This indicates that LZTR1 must be considered when making a diagnosis of NF2 in the presence of unilateral VS in individuals without a germline NF2 mutation.

摘要

目的

确定2型神经纤维瘤病(NF2)当前临床诊断标准相对于单侧前庭神经鞘瘤(VS)及至少2种其他NF2相关肿瘤要求的特异性。

方法

我们查询了曼彻斯特NF2数据库,该数据库包含205名符合NF2标准且最初表现为单侧VS的个体。其中,83例(40.7%)随后发生了对侧VS。我们将基因分析集中在一组70名最初符合NF2标准、患有单侧前庭神经鞘瘤且至少有2种额外非皮内神经鞘瘤的个体上。

结果

总体而言,5/70(7%)患有单侧VS且至少有2种其他神经鞘瘤的个体存在致病性或可能致病性的LZTR1突变。70例中有20例随后发展为双侧疾病。在其余50例中,5例(10%)有生殖系LZTR1突变,与有生殖系NF2突变的数量(n = 5)相当。

结论

该队列中单侧VS及另外2种NF2相关肿瘤最常见的病因是嵌合型NF2。在我们的队列中,生殖系LZTR1和生殖系NF2突变同样常见。这表明在对无生殖系NF2突变且存在单侧VS的个体进行NF2诊断时,必须考虑LZTR1。

相似文献

1
Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Neurology. 2017 Jan 3;88(1):87-92. doi: 10.1212/WNL.0000000000003418. Epub 2016 Nov 16.
2
Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
Neurology. 2015 Jan 13;84(2):141-7. doi: 10.1212/WNL.0000000000001129. Epub 2014 Dec 5.
3
Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
Hum Genet. 2018 Jul;137(6-7):543-552. doi: 10.1007/s00439-018-1909-9. Epub 2018 Jul 13.
5
Sporadic vestibular schwannoma: a molecular testing summary.
J Med Genet. 2021 Apr;58(4):227-233. doi: 10.1136/jmedgenet-2020-107022. Epub 2020 Jun 23.
6
Schwannomatosis: a genetic and epidemiological study.
J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1215-1219. doi: 10.1136/jnnp-2018-318538. Epub 2018 Jun 16.
7
Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation.
J Neurosurg. 2016 Dec;125(6):1469-1471. doi: 10.3171/2015.11.JNS151766. Epub 2016 Feb 5.
9
Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
Am J Med Genet A. 2012 Jan;158A(1):215-9. doi: 10.1002/ajmg.a.34376. Epub 2011 Nov 21.

引用本文的文献

2
Quality of life assessment in schwannomatosis - A systematic review.
Brain Spine. 2025 May 22;5:104279. doi: 10.1016/j.bas.2025.104279. eCollection 2025.
3
Emerging strategies for the prediction of behaviour, growth, and treatment response in vestibular schwannoma.
Acta Neurochir (Wien). 2025 Apr 22;167(1):116. doi: 10.1007/s00701-025-06522-7.
6
Typical NF2 and LTZR1 mutations are retained in an immortalized human schwann cell model of schwannomatosis.
Heliyon. 2024 Oct 4;10(19):e38957. doi: 10.1016/j.heliyon.2024.e38957. eCollection 2024 Oct 15.
7
The Multimodality Management of Malignant Peripheral Nerve Sheath Tumours.
Cancers (Basel). 2024 Sep 26;16(19):3266. doi: 10.3390/cancers16193266.
9
Historical Development of Diagnostic Criteria for NF2-related Schwannomatosis.
Neurol Med Chir (Tokyo). 2024 Aug 15;64(8):299-308. doi: 10.2176/jns-nmc.2024-0067. Epub 2024 Jun 19.
10
F-FDG PET/CT revealed sporadic schwannomatosis involving the lumbar spinal canal and both lower limbs: a case report.
Front Med (Lausanne). 2024 Mar 20;11:1346647. doi: 10.3389/fmed.2024.1346647. eCollection 2024.

本文引用的文献

2
Bilateral vestibular schwannomas in older patients: NF2 or chance?
J Med Genet. 2015 Jun;52(6):422-4. doi: 10.1136/jmedgenet-2014-102973. Epub 2015 Feb 27.
3
Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
Neurology. 2015 Jan 13;84(2):141-7. doi: 10.1212/WNL.0000000000001129. Epub 2014 Dec 5.
4
SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors.
Cancer Genet. 2014 Sep;207(9):373-8. doi: 10.1016/j.cancergen.2014.04.001. Epub 2014 Apr 8.
5
Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.
Nat Genet. 2014 Feb;46(2):182-7. doi: 10.1038/ng.2855. Epub 2013 Dec 22.
6
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.
7
Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
Am J Med Genet A. 2012 Jan;158A(1):215-9. doi: 10.1002/ajmg.a.34376. Epub 2011 Nov 21.
8
Genetic testing and screening of individuals at risk of NF2.
Clin Genet. 2012 Nov;82(5):416-24. doi: 10.1111/j.1399-0004.2011.01816.x. Epub 2011 Dec 16.
9
Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.
Clin Genet. 2008 Oct;74(4):358-66. doi: 10.1111/j.1399-0004.2008.01060.x. Epub 2008 Jul 21.
10
Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.
J Med Genet. 2008 Jun;45(6):332-9. doi: 10.1136/jmg.2007.056499. Epub 2008 Feb 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验